CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

NCT00702923 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Enrollment was halted prematurely due to slow accrual.

Conditions

Prostate Cancer

Interventions

DRUG: Bicalutamide and CP-675,206 (Tremelimumab)
DRUG: Bicalutamide, CP-675,206 (tremelimumab)
DRUG: Bicalutamide, CP-675,206 (Tremelimumab)
DRUG: Bicalutamide, CP-675,206 (Tremelimumab)
DRUG: Bicalutamide, CP-675,206

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]